Company
Immutep Limited
ASX:IMM
Immutep develops immunotherapies built around LAG-3, an immune checkpoint protein that regulates T-cell activity. Its portfolio runs in two directions from the same biology: agonist-style candidates (led by eftilagimod alfa, a soluble LAG-3 protein) intended to stimulate antigen-presenting cells and T-cells against tumours, and antagonist candidates intended to damp down T-cell activity in autoimmune disease. That two-sided position on T-cell regulation is what makes it relevant to the immune-ageing (immunosenescence) axis rather than to a single tumour type. It is not a geroscience company and does not run ageing-endpoint trials; the longevity link is mechanistic, via immune regulation, not by stated intent. Inclusion is on both limbs of the rule: ASX-listed and Sydney-headquartered. The honest negative: its most advanced oncology programme failed a Phase III interim futility analysis in March 2026, so the near-term clinical case rests on the remaining earlier-stage assets.
At a glance
- Listing
- ASX:IMM
- Category
- ASX listed
- Headquarters
- Sydney, New South Wales, Australia
- Market cap
- Not disclosed
Thesis
Why it is in this universe
- Category
- ASX listed
- Market
- Australia
- Recent inflection
- 13 March 2026: the Independent Data Monitoring Committee recommended discontinuing the Phase III TACTI-004 trial of eftilagimod alfa in first-line non-small cell lung cancer following a planned interim futility analysis. Enrolment was halted and the study wound down. The company said its cash runway would extend well beyond the previously guided Q2 CY2027, without giving a revised figure at the time. Immutep's Nasdaq ADRs fell from US$2.76 to US$0.48 on the announcement, about 83 percent. Source: GlobeNewswire company release, 13 March 2026.
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:IMM |
| Secondary listing | NASDAQ |
| Market cap | Not disclosed |
| Status | Listed and trading |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Sydney, New South Wales, Australia
- Website
- www.immutep.com
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
13 March 2026: the Independent Data Monitoring Committee recommended discontinuing the Phase III TACTI-004 trial of eftilagimod alfa in first-line non-small cell lung cancer following a planned interim futility analysis. Enrolment was halted and the study wound down. The company said its cash runway would extend well beyond the previously guided Q2 CY2027, without giving a revised figure at the time. Immutep's Nasdaq ADRs fell from US$2.76 to US$0.48 on the announcement, about 83 percent. Source: GlobeNewswire company release, 13 March 2026.
Common questions
- Why does variis track Immutep Limited?
- Immutep develops immunotherapies built around LAG-3, an immune checkpoint protein that regulates T-cell activity. Its portfolio runs in two directions from the same biology: agonist-style candidates (led by eftilagimod alfa, a soluble LAG-3 protein) intended to stimulate antigen-presenting cells and T-cells against tumours, and antagonist candidates intended to damp down T-cell activity in autoimmune disease. That two-sided position on T-cell regulation is what makes it relevant to the immune-ageing (immunosenescence) axis rather than to a single tumour type. It is not a geroscience company and does not run ageing-endpoint trials; the longevity link is mechanistic, via immune regulation, not by stated intent. Inclusion is on both limbs of the rule: ASX-listed and Sydney-headquartered. The honest negative: its most advanced oncology programme failed a Phase III interim futility analysis in March 2026, so the near-term clinical case rests on the remaining earlier-stage assets.
- Is Immutep Limited publicly listed?
- Yes. It trades as ASX:ASX:IMM. variis records the listing, not a live price.
- Where is Immutep Limited based?
- Sydney, New South Wales, Australia
- Is Immutep Limited still trading?
- Immutep Limited is recorded as actively trading.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Immutep: LAG-3 immunotherapy, four clinical-stage assets in oncology and autoimmune disease; HQ Level 32, Australia Square, 264 George Street, Sydney NSW 2000 · Immutep Limited
- TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis · GlobeNewswire (Immutep Limited release, 13 March 2026)
- Immutep hit with securities suit after TACTI-004 trial halt and 83% stock drop · TipRanks
Every entity profile on variis is sourced. Not investment advice.